Rebecca Harrison


I have a background in molecular biology and genetics, with a particular interest in medical genetics and drug treatments. My work focuses on the side effects of drug treatments in schizophrenia, which is part of the neuropsychiatry theme within the National Institute for Health Research (NIHR) Maudsley BRC/U.

I aim to identify biomarkers for drug treatment to improve the clinical management of patients. Additionally, I have been involved in public engagement at the NIHR doctoral trying camp in science and communication, and I was a member of the winning team.

BA Natural Sciences (Genetics), University of Cambridge

Genetics of Clozapine in Schizophrenia: Harnessing the Power of Clinical Samples

It is a large scale genetic and pharmacogenomic study of schizophrenia. This aims to investigate genetic and clinical influences on the level of clozapine found in the blood plasma, and on clozapine-induced weight gain. The latter is a prevalent side effect of clozapine treatment, and can lead to discontinuation and hence relapses. I chose this particular project as it combines my interest in pharmacology and genetics in a clinically relevant way. 


Dr Gerome Breen and Dr Simone De Jong

Research Team

BRC Bioresource




Bioresource collects biological samples such as blood and saliva for molecular analysis which are linked to electronic medical records of people who have agreed to participate in research.



Training & development

We aim to attract outstanding candidates with a range of experience and offer a variety of training schemes and secondment opportunities, spanning all academic career pathways.


News and Events